Lilian Garcia, MD
Family Medicine · Pembroke Pines, FLNPI 1437101318
Payments from drug & device makers
Across 230 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$843
- Amgen$677
- Novo Nordisk$585
- Lilly USA, LLC$584
- AstraZeneca$431
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$343
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,05798%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 6 | $843 |
| Amgen | 21 | $677 |
| Novo Nordisk | 32 | $585 |
| Lilly USA, LLC | 35 | $584 |
| AstraZeneca | 19 | $431 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $343 |
| GSK | 7 | $234 |
| Boehringer Ingelheim | 7 | $218 |
| Amarin Pharma, Inc. | 10 | $209 |
| Abbott | 5 | $203 |
| Kowa Pharmaceuticals America, Inc. | 12 | $192 |
| Pfizer | 10 | $171 |
| Antares Pharma, Inc. | 8 | $162 |
| Davol Inc. | 1 | $147 |
| Dexcom, Inc. | 6 | $136 |
| Halozyme Inc | 9 | $129 |
| Cardiovascular Systems Inc. | 1 | $115 |
| Astellas Pharma US Inc | 2 | $113 |
| Idorsia Pharmaceuticals US Inc | 6 | $107 |
| Merck | 5 | $92 |
| AbbVie | 5 | $84 |
| Biogen | 4 | $72 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Hologic Sales And Service, LLC | 1 | $37 |
| Radius Health, Inc. | 1 | $33 |
| Johnson & Johnson | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Bayer | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$843
- NEXLETOL$843
- CAPLYTA$250
- Repatha$222
- ARISTA AH FLEXITIP$147
- Prolia$125
- MOUNJARO$117
- Peripheral Orbital Atherectomy System$115
- FARXIGA$112
How this compares
$6,175 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 60 | $83,850 |
| FarxigaDapagliflozin Propanediol | 61 | $71,087 |
| OzempicSemaglutide | 48 | $54,814 |
| TrulicityDulaglutide | 26 | $49,955 |
| EliquisApixaban | 36 | $41,216 |
| XareltoRivaroxaban | 14 | $20,865 |
| ProliaDenosumab | 11 | $19,109 |
| GlyxambiEmpagliflozin/Linagliptin | 16 | $17,232 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $11,656 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,258 |
| SynthroidLevothyroxine Sodium | 28 | $3,912 |
| Atorvastatin Calcium | 375 | $2,419 |
| Omeprazole | 120 | $2,147 |
| Rosuvastatin Calcium | 112 | $1,384 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $1,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $218 | $101,08376 claims |
| AstraZenecaFarxiga | $431 | $71,08761 claims |
| Novo NordiskOzempic | $585 | $54,81448 claims |
| Lilly USA, LLCTrulicity | $584 | $49,95526 claims |
| PfizerEliquis | $171 | $41,21636 claims |
| Johnson & JohnsonXarelto | $33 | $20,86514 claims |
| AmgenProlia | $677 | $19,10911 claims |
| AbbVieSynthroid | $84 | $3,91228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Pembroke Pines
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.